Annual Report 2023: CEO video statement

In 2023, we increased our revenue by 29% in our CRO service business. This is a company record. In Discovery & Partnerships, we also made significant advances last year. We signed two new partnerships with Hemab and Boehringer Ingelheim. We upgraded our AI based peptide drug discovery platform streaMLine opening up new opportunities for us; and we took an important step forward as a company when we dosed the first human in a Phase 1 clinical trial with our internal developed amylin agonist (GUBamy) for the treatment of obesity.

Contacts at Gubra
Media: Sofia Pitt Boserup, [email protected], +45 4188 9586
Investors: Kristian Borbos, [email protected], +45 3080 8035